Biogen expands immunology footprint with US$1B acquisition of RayThera

USA—Biogen has agreed to acquire RayThera, a biotechnology company focused on small-molecule therapies in immunology, in a transaction valued at up to US$1 billion.

The agreement includes an upfront payment, along with milestone-based payouts tied to clinical progress and regulatory approvals, reflecting Biogen’s continued push to expand its presence in immune-mediated diseases.

RayThera contributes a pipeline of experimental therapies, including a lead candidate expected to enter Phase I clinical trials in early Q3 2026, marking a key step toward human testing.

Expanding anti-inflammatory and immune disease programs

Under the agreement, Biogen will integrate RayThera’s portfolio of anti-inflammatory and immune-modulating candidates into its broader research and development engine.

The assets target a range of immune-mediated conditions, where inflammation plays a central role in disease progression.

While detailed program data remains limited, both companies confirmed that multiple candidates are positioned across early development stages, with the lead molecule advancing toward first-in-human studies within the coming year.

In addition, Biogen will assume full responsibility for the development, manufacturing, and eventual global commercialisation of the acquired assets, reinforcing its long-term pipeline strategy.

Leadership perspectives on the acquisition

Biogen executive vice-president and head of development Priya Singhal said the acquisition will deepen the company’s immunology portfolio while enabling expansion into additional disease areas.

She noted that the added programs could strengthen long-term innovation potential and accelerate clinical entry for early-stage candidates.

RayThera co-founder, chairman, and chief executive officer Qing Dong said Biogen’s established global development expertise in immunology makes it a strong fit to advance the pipeline.

He added that the collaboration reflects confidence in the scientific foundation built by RayThera’s team and the rapid progress achieved so far.

Transaction structure, financing, and closing timeline

The financial structure of the deal combines an upfront payment with contingent milestone-based payments tied to development and regulatory achievements, bringing the total value to up to US$1 billion.

The acquisition remains subject to customary closing conditions, including regulatory approvals, and is expected to be completed in the third quarter of 2026.

RayThera recently completed its Series A funding round, co-led by OrbiMed Advisors and Foresite Capital, with participation from TTM Capital, strengthening its early-stage research capacity prior to the acquisition announcement.

Recent regulatory momentum at Biogen

In parallel with its acquisition strategy, Biogen has continued to advance its internal pipeline.

Earlier this month, the US Food and Drug Administration granted breakthrough therapy designation to salanersen (BIIB115), an investigational treatment for spinal muscular atrophy.

The designation highlights the therapy’s potential in addressing a serious neurological condition and supports accelerated development pathways.

The update adds to Biogen’s ongoing efforts to reinforce its neuroscience and rare disease portfolio while complementing its growing focus on immunology-driven programs.